View source for 5-HT7 receptor

{{DISPLAYTITLE:5-HT<sub>7</sub> receptor}}
{{Infobox_gene}}
 
The '''5-HT<sub>7</sub> receptor''' is a member of the [[G-protein coupled receptor|GPCR]] superfamily of cell surface [[receptor (biochemistry)|receptors]] and is activated by the [[neurotransmitter]] [[serotonin]] (5-hydroxytryptamine, 5-HT)<ref name="pmid10664612">{{cite journal | vauthors = Vanhoenacker P, Haegeman G, Leysen JE | title = 5-HT7 receptors: current knowledge and future prospects | journal = Trends in Pharmacological Sciences | volume = 21 | issue = 2 | pages = 70–7 | date = February 2000 | pmid = 10664612 | doi = 10.1016/S0165-6147(99)01432-7 }}</ref> The 5-HT<sub>7</sub> receptor is coupled to [[Heterotrimeric G protein|G<sub>s</sub>]] (stimulates the production of the intracellular signaling molecule [[Cyclic adenosine monophosphate|cAMP]])<ref name="pmid8397408">{{cite journal | vauthors = Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, Schwartz JC | title = Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 90 | issue = 18 | pages = 8547–51 | date = September 1993 | pmid = 8397408 | pmc = 47394 | doi = 10.1073/pnas.90.18.8547 }}</ref><ref name="pmid8226867">{{cite journal | vauthors = Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL | title = Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase | journal = The Journal of Biological Chemistry | volume = 268 | issue = 31 | pages = 23422–6 | date = November 1993 | pmid = 8226867 | doi =  }}</ref> and is expressed in a variety of human tissues, particularly in the brain, the gastrointestinal tract, and in various blood vessels.<ref name="pmid8226867"/> This receptor has been a drug development target for the treatment of several clinical disorders.<ref name="pmid18301795">{{cite journal | vauthors = Mnie-Filali O, Lambás-Señas L, Zimmer L, Haddjeri N | title = 5-HT7 receptor antagonists as a new class of antidepressants | journal = Drug News & Perspectives | volume = 20 | issue = 10 | pages = 613–8 | date = December 2007 | pmid = 18301795 | doi = 10.1358/dnp.2007.20.10.1181354 }}</ref> The 5-HT<sub>7</sub> receptor is encoded by the ''HTR7'' [[gene]], which in humans is transcribed into 3 different splice variants.<ref name="pmid9084407">{{cite journal | vauthors = Heidmann DE, Metcalf MA, Kohen R, Hamblin MW | title = Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organization | journal = Journal of Neurochemistry | volume = 68 | issue = 4 | pages = 1372–81 | date = April 1997 | pmid = 9084407 | doi = 10.1046/j.1471-4159.1997.68041372.x }}</ref>

== Function ==

When the 5-HT<sub>7</sub> receptor is activated by serotonin, it sets off a cascade of events starting with release of the stimulatory [[heterotrimeric G protein|G protein]] [[Gs alpha subunit|G<sub>s</sub>]] from the GPCR complex.  G<sub>s</sub> in turn activates [[adenylate cyclase]] which increases [[intracellular]] levels of the [[second messenger system|second messenger]] [[cyclic adenosine monophosphate|cAMP]].

The 5-HT<sub>7</sub> receptor plays a role in [[smooth muscle]] [[muscle relaxant|relaxation]] within the [[vasculature]] and in the [[gastrointestinal tract]].<ref name="pmid10664612"/> The highest 5-HT<sub>7</sub> receptor densities are in the [[thalamus]] and [[hypothalamus]], and it is present at higher densities also in the [[hippocampus]] and [[Cerebral cortex|cortex]]. The 5-HT<sub>7</sub> receptor is involved in [[thermoregulation]], [[circadian rhythm]], [[learning]] and [[memory]], and [[sleep]]. It is also speculated that this receptor may be involved in [[Mood (psychology)|mood]] regulation, suggesting that it may be a useful target in the treatment of [[major depression|depression]].<ref name="pmid15559250">{{cite journal | vauthors = Hedlund PB, Sutcliffe JG | title = Functional, molecular and pharmacological advances in 5-HT7 receptor research | journal = Trends in Pharmacological Sciences | volume = 25 | issue = 9 | pages = 481–6 | date = September 2004 | pmid = 15559250 | doi = 10.1016/j.tips.2004.07.002 }}</ref><ref>{{cite journal | vauthors = Naumenko VS, Popova NK, Lacivita E, Leopoldo M, Ponimaskin EG | title = Interplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disorders | journal = CNS Neuroscience & Therapeutics | volume = 20 | issue = 7 | pages = 582–90 | date = July 2014 | pmid = 24935787 | doi = 10.1111/cns.12247 }}</ref>

== Variants ==

Three [[alternative splicing|splice variants]] have been identified in humans (designated h5-HT<sub>7(a)</sub>, h5-HT<sub>7(b)</sub>, and h5-HT<sub>7(d)</sub>), which encode receptors that differ in their [[C-terminus|carboxy terminals]].<ref name="pmid9084407" /> The h5-HT<sub>7(a)</sub> is the full length receptor (445 amino acids),<ref name="pmid8226867"/> while the h5-HT<sub>7(b)</sub> is truncated at amino acid 432 due to alternative splice donor site. The h5-HT<sub>7(d)</sub> is a distinct isoform of the receptor: the retention of an exon cassette in the region encoding the carboxyl terminal results a 479-amino acid receptor with a c-terminus markedly different from the h5-HT<sub>7(a)</sub>. A 5-HT<sub>7(c)</sub> splice variant is detectable in rat tissue but is not expressed in humans. Conversely, rats do not express a splice variant homologous to the h5-HT<sub>7(d)</sub>, as the rat 5-HT<sub>7</sub> gene lacks the exon necessary to encode this isoform.<ref name="pmid9084407"/> Drug binding affinities are similar across the three human splice variants;<ref name="pmid11414657">{{cite journal | vauthors = Krobert KA, Bach T, Syversveen T, Kvingedal AM, Levy FO | title = The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution | journal = Naunyn-Schmiedeberg's Archives of Pharmacology | volume = 363 | issue = 6 | pages = 620–32 | date = June 2001 | pmid = 11414657 | doi = 10.1007/s002100000369 }}</ref> however, inverse agonist efficacies appear to differ between the splice variants.<ref name="pmid11906971">{{cite journal | vauthors = Krobert KA, Levy FO | title = The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects | journal = British Journal of Pharmacology | volume = 135 | issue = 6 | pages = 1563–71 | date = March 2002 | pmid = 11906971 | pmc = 1573253 | doi = 10.1038/sj.bjp.0704588 }}</ref>

== Discovery ==

In 1983, evidence for a [[5-HT1|5-HT<sub>1</sub>]]-like receptor was first found.<ref>{{cite journal | vauthors = Feniuk W, Humphrey PP, Watts AD | title = 5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle | journal = European Journal of Pharmacology | volume = 96 | issue = 1–2 | pages = 71–8 | date = December 1983 | pmid = 6662198 | doi = 10.1016/0014-2999(83)90530-7 }}</ref> Ten years later, 5-HT<sub>7</sub> receptor was cloned and characterized.<ref name="pmid8226867" /> It has since become clear that the receptor described in 1983 is 5-HT<sub>7</sub>.<ref>{{cite journal | vauthors = Hoyer D, Hannon JP, Martin GR | title = Molecular, pharmacological and functional diversity of 5-HT receptors | journal = Pharmacology, Biochemistry, and Behavior | volume = 71 | issue = 4 | pages = 533–54 | date = April 2002 | pmid = 11888546 | doi = 10.1016/S0091-3057(01)00746-8 }}</ref>

== Clinical significance ==

This receptor gene is a candidate [[gene locus|locus]] for involvement in [[autism|autistic]] disorder and other neuropsychiatric disorders.<ref name="pmid10490701">{{cite journal | vauthors = Lassig JP, Vachirasomtoon K, Hartzell K, Leventhal M, Courchesne E, Courchesne R, Lord C, Leventhal BL, Cook EH | title = Physical mapping of the serotonin 5-HT(7) receptor gene (HTR7) to chromosome 10 and pseudogene (HTR7P) to chromosome 12, and testing of linkage disequilibrium between HTR7 and autistic disorder | journal = American Journal of Medical Genetics | volume = 88 | issue = 5 | pages = 472–5 | date = October 1999 | pmid = 10490701 | doi = 10.1002/(SICI)1096-8628(19991015)88:5<472::AID-AJMG7>3.0.CO;2-G }}</ref>

== Ligands ==

Numerous ligands [[binding (molecular)|bind]] to the 5-HT<sub>7</sub> receptor with moderate to high affinity.

=== Agonists ===

[[Agonists]] mimic the effects of the endogenous ligand, which is serotonin at the 5-HT<sub>7</sub> receptor (↑cAMP).
{{div col|30em}}
* [[5-Carboxamidotryptamine]] (5-CT)
* [[5-methoxytryptamine]] (5-MT, 5-MeOT)
* [[8-OH-DPAT]] (mixed [[5-HT1A receptor|5-HT<sub>1A</sub>]]/5-HT<sub>7</sub> agonist)<ref name="pmid14654097">{{cite journal | vauthors = Sprouse J, Reynolds L, Li X, Braselton J, Schmidt A | title = 8-OH-DPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production | journal = Neuropharmacology | volume = 46 | issue = 1 | pages = 52–62 | date = January 2004 | pmid = 14654097 | doi = 10.1016/j.neuropharm.2003.08.007 }}</ref>
* [[Aripiprazole]] (weak [[partial agonist]])<ref>Davies MA, Sheffler DJ, Roth BL. Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology. CNS Drug Reviews [Internet]. 2004 [cited 2013 Aug 4];10(4):317–36. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00030.x/pdf</ref>
* [[AS-19 (drug)|AS-19]]
* [[E-55888]]<ref name="pmid21778664">{{cite journal | vauthors = Brenchat A, Ejarque M, Zamanillo D, Vela JM, Romero L | title = Potentiation of morphine analgesia by adjuvant activation of 5-HT7 receptors | journal = Journal of Pharmacological Sciences | volume = 116 | issue = 4 | pages = 388–91 | date = August 2011 | pmid = 21778664 | doi = 10.1254/jphs.11039sc }}</ref>
* [[E-57431]]<ref name="pmid20399562">{{cite journal | vauthors = Brenchat A, Nadal X, Romero L, Ovalle S, Muro A, Sánchez-Arroyos R, Portillo-Salido E, Pujol M, Montero A, Codony X, Burgueño J, Zamanillo D, Hamon M, Maldonado R, Vela JM | title = Pharmacological activation of 5-HT7 receptors reduces nerve injury-induced mechanical and thermal hypersensitivity | journal = Pain | volume = 149 | issue = 3 | pages = 483–94 | date = June 2010 | pmid = 20399562 | doi = 10.1016/j.pain.2010.03.007 }}</ref>
* [[LP-12]] (4-(2-Diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide)
* [[LP-44]] (4-[2-(Methylthio)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-1-piperazinehexanamide)
* [[LP-211]]
* [[LSD]]
* [[MSD-5a]]<ref name="pmid19118950">{{cite journal | vauthors = Brenchat A, Romero L, García M, Pujol M, Burgueño J, Torrens A, Hamon M, Baeyens JM, Buschmann H, Zamanillo D, Vela JM | title = 5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice | journal = Pain | volume = 141 | issue = 3 | pages = 239–47 | date = February 2009 | pmid = 19118950 | doi = 10.1016/j.pain.2008.11.009 }}</ref>
* [[N-Methylserotonin|''N<sub>ω</sub>''-Methylserotonin]]<ref name="Powell et al.">{{cite journal | vauthors = Powell SL, Gödecke T, Nikolic D, Chen SN, Ahn S, Dietz B, Farnsworth NR, van Breemen RB, Lankin DC, Pauli GF, Bolton JL | title = In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent | journal = Journal of Agricultural and Food Chemistry | volume = 56 | issue = 24 | pages = 11718–26 | date = December 2008 | pmid = 19049296 | pmc = 3684073 | doi = 10.1021/jf803298z }}</ref>
* ''N''-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides (can function as either an agonist or antagonist depending on side chain substitution)<ref name="pmid17649988">{{cite journal | vauthors = Leopoldo M, Lacivita E, Contino M, Colabufo NA, Berardi F, Perrone R | title = Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2 | journal = Journal of Medicinal Chemistry | volume = 50 | issue = 17 | pages = 4214–21 | date = August 2007 | pmid = 17649988 | doi = 10.1021/jm070487n }}</ref><ref name="pmid15588097">{{cite journal | vauthors = Leopoldo M, Berardi F, Colabufo NA, Contino M, Lacivita E, Niso M, Perrone R, Tortorella V | title = Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents | journal = Journal of Medicinal Chemistry | volume = 47 | issue = 26 | pages = 6616–24 | date = December 2004 | pmid = 15588097 | doi = 10.1021/jm049702f }}</ref>
* [[N,N-Dimethyltryptamine]]
* [[1-(2-Diphenyl)piperazine|RA-7]] (1-(2-diphenyl)piperazine)
{{Div col end}}

=== Antagonists ===

[[receptor antagonist|Neutral antagonists]] (also known as silent antagonists) bind the receptor and have no [[Efficacy|intrinsic activity]] but will block the activity of agonists or inverse agonists. [[Inverse agonists]] inhibit the [[Receptor (biochemistry)#Constitutive activity|constitutive activity]] of the receptor, producing functional effects opposite to those of agonists (at the 5-HT<sub>7</sub> receptor: ↓cAMP).<ref name="pmid17897083">{{cite journal | vauthors = Pittalà V, Salerno L, Modica M, Siracusa MA, Romeo G | title = 5-HT7 receptor ligands: recent developments and potential therapeutic applications | journal = Mini Reviews in Medicinal Chemistry | volume = 7 | issue = 9 | pages = 945–60 | date = September 2007 | pmid = 17897083 | doi = 10.2174/138955707781662663 }}</ref><ref name="pmid15032609">{{cite journal | vauthors = Leopoldo M | title = Serotonin(7) receptors (5-HT(7)Rs) and their ligands | journal = Current Medicinal Chemistry | volume = 11 | issue = 5 | pages = 629–61 | date = March 2004 | pmid = 15032609 | doi = 10.2174/0929867043455828 }}</ref> Neutral antagonists and inverse agonists are typically referred to collectively as "antagonists" and, in the case of the 5-HT<sub>7</sub> receptor, differentiation between neutral antagonists and inverse agonists is problematic due to differing levels inverse agonist efficacy between receptor splice variants. For instance, mesulergine and metergoline are reported to be neutral antagonists at the h5-HT<sub>7(a)</sub> and h5-HT<sub>7(d)</sub> receptor isoforms but these drugs display marked inverse agonist effects at the h5-HT<sub>7(b)</sub> splice variant.<ref name="pmid11906971"/>

{{div col|3}}
* 3-{4-[4-(4-chlorophenyl)-piperazin-1-yl]-butyl}-3-ethyl-6-fluoro-1,3-dihydro-2''H''-indol-2-one<ref name="pmid18361484">{{cite journal | vauthors = Volk B, Barkóczy J, Hegedus E, Udvari S, Gacsályi I, Mezei T, Pallagi K, Kompagne H, Lévay G, Egyed A, Hársing LG, Spedding M, Simig G | title = (Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists | journal = Journal of Medicinal Chemistry | volume = 51 | issue = 8 | pages = 2522–32 | date = April 2008 | pmid = 18361484 | doi = 10.1021/jm070279v }}</ref>
* [[Amisulpride]]<ref name="pmid19337725">{{cite journal | vauthors = Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL | title = Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo | journal = Psychopharmacology | volume = 205 | issue = 1 | pages = 119–28 | date = July 2009 | pmid = 19337725 | pmc = 2821721 | doi = 10.1007/s00213-009-1521-8 }}</ref>
* [[Amitriptyline]]
* [[Amoxapine]]
* [[Clomipramine]]
* [[Clozapine]]
* [[DR-4485]]
* [[EGIS-12233]] (mixed 5-HT<sub>6</sub>/5-HT<sub>7</sub> antagonist)
* [[Fluphenazine]]
* [[Fluperlapine]]
* [[ICI 169,369]]
* [[Imipramine]]
* [[JNJ-18038683]]
* [[Ketanserin]]
* [[Loxapine]]
* [[Lurasidone]]
* [[LY-215,840]]
* [[Maprotiline]]
* [[Mesulergine]]
* [[Methysergide]]
* [[Mianserin]]
* [[Olanzapine]]
* [[Pimozide]]
* [[Ritanserin]]
* [[SB-258,719]]<ref name="pmid16967291"/><ref name="pmid9513592">{{cite journal | vauthors = Forbes IT, Dabbs S, Duckworth DM, Jennings AJ, King FD, Lovell PJ, Brown AM, Collin L, Hagan JJ, Middlemiss DN, Riley GJ, Thomas DR, Upton N | title = (R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist | journal = Journal of Medicinal Chemistry | volume = 41 | issue = 5 | pages = 655–7 | date = February 1998 | pmid = 9513592 | doi = 10.1021/jm970519e }}</ref><ref name="pmid15249157">{{cite journal | vauthors = Mahé C, Loetscher E, Feuerbach D, Müller W, Seiler MP, Schoeffter P | title = Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors | journal = European Journal of Pharmacology | volume = 495 | issue = 2–3 | pages = 97–102 | date = July 2004 | pmid = 15249157 | doi = 10.1016/j.ejphar.2004.05.033 }}</ref>
* [[SB-258741]]<ref name="pmid15249157"/>
* [[SB-269970]] (highly 5-HT<sub>7</sub> selective)<ref name="pmid10669560">{{cite journal | vauthors = Lovell PJ, Bromidge SM, Dabbs S, Duckworth DM, Forbes IT, Jennings AJ, King FD, Middlemiss DN, Rahman SK, Saunders DV, Collin LL, Hagan JJ, Riley GJ, Thomas DR | title = A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970) | journal = Journal of Medicinal Chemistry | volume = 43 | issue = 3 | pages = 342–5 | date = February 2000 | pmid = 10669560 | doi = 10.1021/jm991151j }}</ref>
* [[SB-656104-A]]<ref name="pmid12392747">{{cite journal | vauthors = Forbes IT, Douglas S, Gribble AD, Ife RJ, Lightfoot AP, Garner AE, Riley GJ, Jeffrey P, Stevens AJ, Stean TO, Thomas DR | title = SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties | journal = Bioorganic & Medicinal Chemistry Letters | volume = 12 | issue = 22 | pages = 3341–4 | date = November 2002 | pmid = 12392747 | doi = 10.1016/S0960-894X(02)00690-X }}</ref>
* [[SB-691673]]<ref name="pmid16967291">{{cite journal | vauthors = Romero G, Pujol M, Pauwels PJ | title = Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists | journal = Naunyn-Schmiedeberg's Archives of Pharmacology | volume = 374 | issue = 1 | pages = 31–9 | date = October 2006 | pmid = 16967291 | doi = 10.1007/s00210-006-0093-y }}</ref>
* [[Sertindole]]
* [[Spiperone]]
* [[Tenilapine]]
* [[TFMPP]]
* [[Vortioxetine]]
* [[Trifluoperazine]]
* [[Ziprasidone]]
* [[Zotepine]]
{{Div col end}}

==== Inactivating antagonists ====

Inactivating antagonists are non-competitive antagonists that render the receptor persistently insensitive to agonist, which resembles receptor desensitization. Inactivation of the 5-HT<sub>7</sub> receptor, however, does not arise from the classically described mechanisms of receptor desensitization via receptor phosphorylation, beta-arrestin recruitment, and receptor internalization.<ref name="pmid9606723">{{cite journal | vauthors = Zhang J, Ferguson SS, Barak LS, Aber MJ, Giros B, Lefkowitz RJ, Caron MG | title = Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization | journal = Receptors & Channels | volume = 5 | issue = 3–4 | pages = 193–9 | year = 1997 | pmid = 9606723 }}</ref> Inactivating antagonists all likely interact with the 5-HT<sub>7</sub> receptor in an irreversible/pseudo-irreversible manner, as is the case with [<sup>3</sup>H]risperidone.<ref name="pmid16870886">{{cite journal | vauthors = Smith C, Rahman T, Toohey N, Mazurkiewicz J, Herrick-Davis K, Teitler M | title = Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor | journal = Molecular Pharmacology | volume = 70 | issue = 4 | pages = 1264–70 | date = October 2006 | pmid = 16870886 | doi = 10.1124/mol.106.024612 }}</ref><ref name="pmid18996971">{{cite journal | vauthors = Knight JA, Smith C, Toohey N, Klein MT, Teitler M | title = Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists | journal = Molecular Pharmacology | volume = 75 | issue = 2 | pages = 374–80 | date = February 2009 | pmid = 18996971 | pmc = 2671286 | doi = 10.1124/mol.108.052084 }}</ref>
{{div col|30em}}
* [[Bromocriptine]]<ref name="pmid18996971"/>
* [[Lisuride]]<ref name="pmid18996971"/>
* [[Metergoline]]<ref name="pmid18996971"/>
* [[Methiothepin]]<ref name="pmid16870886"/>
* [[Paliperidone]]<ref name="pmid16870886"/>
* [[Risperidone]]<ref name="pmid16870886"/>
{{Div col end}}

== See also ==
{{div col|3}}
* [[5-HT receptor]]
* [[5-HT1 receptor|5-HT<sub>1</sub> receptor]]
* [[5-HT2 receptor|5-HT<sub>2</sub> receptor]]
* [[5-HT3 receptor|5-HT<sub>3</sub> receptor]]
* [[5-HT4 receptor|5-HT<sub>4</sub> receptor]]
* [[5-HT5 receptor|5-HT<sub>5</sub> receptor]]
* [[5-HT6 receptor|5-HT<sub>6</sub> receptor]]
{{Div col end}}

== References ==
{{Reflist|30em}}

== External links ==
* {{cite web | url = http://www.iuphar-db.org/GPCR/ReceptorDisplayForward?receptorID=2337 | title = 5-HT<sub>7</sub>  | accessdate = | authorlink = | format = | work = IUPHAR Database of Receptors and Ion Channels | publisher = International Union of Basic and Clinical Pharmacology | pages = | archiveurl = | archivedate = | quote = }}
* {{UCSC gene info|HTR7}}

{{NLM content}}
{{G protein-coupled receptors}}
{{Serotonergics}}

{{DEFAULTSORT:5-Ht7 Receptor}}

[[Category:Serotonin receptors]]